Correlation Between Chemours and Summit Therapeutics

Can any of the company-specific risk be diversified away by investing in both Chemours and Summit Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Chemours and Summit Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Chemours Co and Summit Therapeutics PLC, you can compare the effects of market volatilities on Chemours and Summit Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Chemours with a short position of Summit Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Chemours and Summit Therapeutics.

Diversification Opportunities for Chemours and Summit Therapeutics

0.05

Correlation Coefficient

Chemours  Summit Therapeutics

Significant diversification

The 3 months correlation between Chemours and Summit is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Chemours Co and Summit Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Summit Therapeutics PLC and Chemours is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Chemours Co are associated (or correlated) with Summit Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Summit Therapeutics PLC has no effect on the direction of Chemours i.e., Chemours and Summit Therapeutics go up and down completely randomly.

Pair Corralation between Chemours and Summit Therapeutics

Allowing for the 90-day total investment horizon Chemours Co is expected to under-perform the Summit Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Chemours Co is 1.31 times less risky than Summit Therapeutics. The stock trades about -0.03 of its potential returns per unit of risk. The Summit Therapeutics PLC is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  2,025  in Summit Therapeutics PLC on October 12, 2024 and sell it today you would lose (143.00) from holding Summit Therapeutics PLC or give up 7.06% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Chemours Co  vs.  Summit Therapeutics PLC

Chemours

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Chemours Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Summit Therapeutics PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Summit Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable primary indicators, Summit Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Chemours and Summit Therapeutics

The main advantage of trading using opposite Chemours and Summit Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Chemours position performs unexpectedly, Summit Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Summit Therapeutics will offset losses from the drop in Summit Therapeutics' long position.

The idea behind Chemours Co and Summit Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.